1. Home
  2. |Insights
  3. |Only One Place to Go for In-sourcing Challenge

Only One Place to Go for In-sourcing Challenge

Client Alert | less than 1 min read | 04.14.14

In Fisher-Cal Indus., Inc. v. U.S. (Apr. 8, 2014), the D.C. Circuit bounced an incumbent's challenge to the agency's in-sourcing decision. Finding the decision to be part of the procurement process, the court ruled that it was, in essence, a bid protest that could be brought only in the Court of Federal Claims.


Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...